Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Mainz Biomed N.V. (MYNZ:NASDAQ), powered by AI.
Mainz Biomed N.V. is currently trading at $1.94. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Mainz Biomed N.V. on Alpha Lenz.
Mainz Biomed N.V.'s P/E ratio is -0.7.
“Mainz Biomed N.V. trades at a P/E of -0.7 (undervalued) with modest ROE of -488.3%.”
Ask for details →Mainz Biomed N.V. is a biotechnology company primarily engaged in the development and commercialization of innovative diagnostic solutions. Headquartered in Mainz, Germany, this dynamic firm is dedicated to the advancement of early cancer detection technologies. Its flagship product focuses on non-invasive cancer screening, which significantly enhances the ability to detect the disease in its initial stages, thus allowing for timely intervention and better patient outcomes. Mainz Biomed operates within the healthcare sector, specifically impacting the diagnostics industry, where there is a continuous demand for precision medicine and effective diagnostic tools. The company plays a notable role in the market by leveraging cutting-edge genetic and genomic testing methodologies, contributing to the broader goal of improving cancer diagnostics. By operating at the intersection of biotechnology and healthcare, Mainz Biomed serves as a pivotal force in advancing medical technology aimed at transforming patient care through early and accurate diagnosis.
“Mainz Biomed N.V. trades at a P/E of -0.7 (undervalued) with modest ROE of -488.3%.”
Ask for details →Mainz Biomed N.V. (ticker: MYNZ) is a company listed on NASDAQ in the Healthcare sector (Diagnostics & Research). It has approximately 19 employees. Market cap is $12M.
The current price is $1.94 with a P/E ratio of -0.72x and P/B of 18.13x.
ROE is -488.32% and operating margin is -2414.04%. Annual revenue is $537,080.